13:15 uur 13-04-2021

Biognosys kondigt strategische overeenkomst aan met Siemens Healthineers

De overeenkomst heeft tot doel het continuüm van diagnostische biomarkerontdekking te versnellen tot en met de ontwikkeling van assays en klinische tests

SCHLIEREN, Zwitserland– (BUSINESS WIRE) – Biognosys, een leider in proteomics-oplossingen van de volgende generatie voor het ontdekken en ontwikkelen van geneesmiddelen, kondigt vandaag aan dat het een strategische overeenkomst heeft gesloten met Siemens Healthineers, een wereldwijd medisch technologiebedrijf, via zijn klinisch laboratorium in Berkeley , Californië. De overeenkomst maakt gebruik van de expertise van Biognosys op het gebied van onbevooroordeelde technologieën en oplossingen voor het ontdekken van biomarkers met de ontwikkeling, laboratoriumtests en commercialiseringsmogelijkheden van Siemens Healthineers op het gebied van biomarkertests.

Oliver Rinner, PhD, CEO en oprichter van Biognosys zegt: “Met deze overeenkomst kunnen we onze biofarmaceutische klanten in staat stellen om de kracht van onze gepatenteerde proteomics-oplossing voor nieuwe biomarkers te gebruiken voor nieuwe biomarkeridentificatie en deze biomarkers in klinische toepassingen te brengen met de diagnostische testontwikkeling van Siemens Healthineers.”

Biognosys Announces Strategic Agreement with Siemens Healthineers

The Agreement Aims to Accelerate the Continuum of Diagnostic Biomarker Discovery through to Assay Development and Clinical Testing

SCHLIEREN, Switzerland–(BUSINESS WIRE)– Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, announces today that it has established a strategic agreement with Siemens Healthineers, a global medical technology company, through its clinical laboratory in Berkeley, California. The agreement leverages Biognosys’ expertise in unbiased biomarker discovery technologies and solutions with Siemens Healthineers’ biomarker assay development, lab testing, and commercialization capabilities.

Oliver Rinner, PhD, CEO and founder of Biognosys states: “With this agreement we can enable our biopharmaceutical customers to use the power of our proprietary discovery proteomics solution for novel biomarker identification and bring these biomarkers into clinical applications with Siemens Healthineers’ diagnostic assay development expertise.”

Using Biognosys’ proprietary Hyper Reaction Monitoring (HRMTM) mass spectrometry technology, thousands of proteins may be quantified simultaneously from a broad range of clinical sample types. HRM enables an unmatched depth of proteome coverage with reproducible and precise quantification to identify the most promising, actionable biomarkers to support clinical decision making. This discovery proteomics solution can be applied with high throughput in large-scale studies involving thousands of samples.

The strategic agreement enables discovery of novel biomarkers via the HRM technology followed by translation into validated biomarker assays for potential clinical applications. This may include clinical trials usage and In Vitro Diagnostics development programs.

Sebastian Kronmueller, Head of Siemens Healthcare Laboratory in California, commented: “We are excited about this relationship with Biognosys because their expertise and unique biomarker discovery capabilities are very complementary to our end-to-end diagnostic solutions for our biopharmaceutical customers.”

About Biognosys

Biognosys is a leader in next-generation proteomics, dedicated to transforming life science by inventing and developing cutting-edge proteomics technology and solutions, and making them widely available for pharmaceutical and biotechnology researchers and proteomics experts. The company’s proprietary solutions provide a multi-dimensional view of protein expression, function, and structure in all major biological species and sample types. Biognosys’ unique, patented technologies utilize high-resolution mass spectrometry for the quantification of thousands of proteins across thousands of samples with industry-leading, precision, depth, and throughput. Through advanced data analytics, Biognosys translates data into actionable insights for R&D and clinical research. More information at biognosys.com.

About Siemens Healthineers

To learn more about Siemens Healthineers, please visit siemens-healthineers.com.


Media Contact Biognosys
Oliver Rinner, PhD
Chief Executive Officer

Phone +41 (0) 44 738 20 40


Media Contact Siemens Healthineers
Lance Longwell, MBA
Director Of Communications And Public Relations

Phone +1 (610) 883-0788


Check out our twitter: @NewsNovumpr